Advance in resistance mechanism of cancer stem cells therapy

CAO Mengxue; SUN Fan; LIN Houwen

doi:10.3969/j.issn.1006-0111.2017.03.001

Message Board

Respected readers, authors and reviewers, you can add comments to this page on any questions about the contribution, review, editing and publication of this journal. We will give you an answer as soon as possible. Thank you for your support!

Name

E-mail

Phone

Title

Content

Verification Code

Volume 35 Issue 3

Turn off MathJax

Article Contents

Article Navigation > Journal of Pharmaceutical Practice and Service > 2017 > 35(3): 193-196,247

CAO Mengxue, SUN Fan, LIN Houwen. Advance in resistance mechanism of cancer stem cells therapy[J]. Journal of Pharmaceutical Practice and Service, 2017, 35(3): 193-196,247. doi: 10.3969/j.issn.1006-0111.2017.03.001

Citation:

CAO Mengxue, SUN Fan, LIN Houwen. Advance in resistance mechanism of cancer stem cells therapy[J]. Journal of Pharmaceutical Practice and Service, 2017, 35(3): 193-196,247. doi: 10.3969/j.issn.1006-0111.2017.03.001

Advance in resistance mechanism of cancer stem cells therapy

doi: 10.3969/j.issn.1006-0111.2017.03.001

1.
College of Traditional Chinese Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China;Renji Hospital, Shanghai Jiaotong University Pharmacy, Shanghai 200127, China
2.
Renji Hospital, Shanghai Jiaotong University Pharmacy, Shanghai 200127, China

Received Date: 2016-02-05
Rev Recd Date: 2016-06-15

Abstract

Lung cancer is the leading cause of cancer deaths worldwide. Recurrence and metastasis are the primary reasons for its poor prognosis. Growing evidence has proposed that lung cancer may be driven by cancer stem cells (CSCs), which may be responsible for the poor outcome of lung cancer. The resistance mechanisms of cancer stem cells include four aspects: high expression of the chemo-resistant efflux transporter ABC in CSCs populations, over-expression of ALDH, efficient DNA damage repair system, developmental pathway activation. The tolerance mechanism of CSCs was described to provide theoretical basis for clinical treatment and development of new anti-tumor drugs.
- cancer stem cells,
- therapy resistance,
- ABC transports,
- ALDH,
- DNA damage repair,
- developmental pathway activation

References

[1]	Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation[J].Cell, 2011, 144 (5): 646-674.
[2]	Chufan EE, Kapoor K, Ambudkar SV. Drug-protein hydrogen bonds govern the inhibition of the ATPhydrolysis of the multidrug transporter P-glycoprotein[J].Biochem Pharmacol, 2016, (101): 40-53.
[3]	Guan GF, Zhang DJ, Zheng Y,et al. Significance of ATP-binding cassette transporter proteins in multidrug resistance of head and neck squamous cell carcinoma[J].Oncol Lett, 2015, 10 (2): 631-636.
[4]	Xie ZY, Lv K, Xiong Y,et al. ABCG2-meditated multidrug resistance and tumor-initiating capacity of side population cells from colon cancer[J]. Oncol Res Treat, 2014, 37 (11): 666-672.
[5]	Stacy AE, Jansson PJ, Richardson DR. Molecular pharmacology of ABCG2 and its role in chemoresistance[J]. Mol Pharmacol, 2013, 84 (5): 655-669.
[6]	Schexnayder C, Stratford RE. Genistein and Glyceollin effects on ABCC2 (MRP2) and ABCG2 (BCRP) in Caco-2 Cells[J]. Int J Environ Res Public Health, 2015, 13 (1):17-30.
[7]	Hu J, Zhang X, Wang F, et al. Effect of ceritinib (LDK378) on enhancement of chemotherapeutic agents in ABCB1 and ABCG2 overexpressing cells in vitro and in vivo[J]. Oncotarget, 2015, 6 (42): 44643-44659.
[8]	Zhou Q, Ye M, Lu Y,et al. Curcumin improves the tumoricidal effect of mitomycin C by suppressing ABCG2 expression in stem cell-like breast cancer cells[J]. PLoS One, 2015, 10 (8): e0136694.
[9]	Rodriguez-Torres M, Allan AL. Aldehyde dehydrogenase as a marker and functional mediator of metastasis in solid tumors[J]. Clin Exp Metastasis, 2016, 33 (1): 97-113.
[10]	Qiu Y, Pu TJ, Guo P, et al. ALDH⁺/CD44⁺cells in breast cancer are associated with worse prognosis and poor clinical outcome[J]. Exp Mol Pathol, 2016, (100): 145-150.
[11]	Moreb JS, Baker HV, Chang LJ,et al. ALDH isozymes downregulation affects cell growth, cell motility and gene expression in lung cancer cells[J]. Mol Cancer, 2008, 7 (87). doi: 10.1186/1476-4598-7-87.
[12]	Mizuno T, Suzuki N, Makino H,et al. Cancer stem-like cells of ovarian clear cell carcinoma are enriched in the ALDH-high population associated with an accelerated scavenging system in reactive oxygen species[J]. Gynecol Oncol, 2015, 137 (2): 299-305.
[13]	Diehn M, Cho RW, Lobo NA,et al. Association of reactive oxygen species levels and radioresistance in cancer stem cells[J]. Nature, 2009, 458 (7239): 780-783.
[14]	Ajani JA, Wang X, Song S,et al. ALDH-1 expression levels predict response or resistance to preoperative chemoradiation in resectable esophageal cancer patients[J]. Mol Oncol, 2014, 8 (1): 142-149.
[15]	Mi JQ, Li JM, Shen ZX,et al. How to manage acute promyelocytic leukemia[J]. Leukemia, 2012, 26 (8): 1743-1751.
[16]	Parajuli B,Fishel ML,Hurley TD.Selective ALDH3A1 inhibition by benzimidazole analogues increase mafosfamide sensitivity in cancer cells[J].J Med Chem,2014,57 (2):449-461.
[17]	Bartucci M, Svensson S, Romania P, et al. Therapeutic targeting of Chk1 in NSCLC stem cells during chemotherapy[J]. Cell Death Differ, 2012, 19 (5): 768-778.
[18]	Chen Y, Li D, Wang D,et al. Quiescence and attenuated DNA damage response promote survival of esophageal cancer stem cells[J]. J Cell Biochem, 2012, 113 (12): 3643-3652.
[19]	Al-Assar O, Mantoni T, Lunardi S,et al. Breast cancer stem-like cells show dominant homologous recombination due to a larger S-G2fraction[J]. Cancer Biol Ther, 2014, 11 (12): 1028-1035.
[20]	Zhang M, Behbod F, Atkinson RL, et al. Identification of tumor-initiating cells in a p53-null mouse model of breast cancer[J]. Cancer Res, 2008, 68 (12): 4674-4682.
[21]	Bao S, Wu Q, Mclendon RE, et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response[J]. Nature, 2006, 444 (7120): 756-760.
[22]	Yin H, Glass J. The phenotypic radiation resistance of CD44⁺/CD24^-/low breast cancer cells is mediated through the enhanced activation of ATM signaling[J]. PLoS One, 2011, 6 (9): e24080.
[23]	Teng Y, Wang X, Wang Y,et al. Wnt/beta-catenin signaling regulates cancer stem cells in lung cancer A549 cells[J]. Biochem Biophys Res Commun, 2010, 392 (3): 373-379.
[24]	Wang Y, Krivtsov AV, Sinha AU,et al. The Wnt/beta-catenin pathway is required for the development of leukemia stem cells in AML[J]. Science, 2010, 327 (5973): 1650-1653.
[25]	Martins-Neves SR, Paiva-Olivira DI, Wijers-Koster PM, et al. Chemotherapy induces stemness in osteosarcoma cells through activation of Wnt/beta-catenin signaling[J]. Cancer Lett, 2016, 370 (2): 286-295.
[26]	Catalano V, Dentice M, Ambrosio R,et al. Activated thyroid hormone promotes differentiation and chemotherapeutic sensitization of colorectal cancer stem cells by regulating Wnt and BMP4 signaling[J]. Cancer Res, 2015, 76 (5): 1237-1244.
[27]	Fang L, Zhu Q, Neuenschwander M,et al. A small-molecule antagonist of the beta-catenin/TCF4 interaction blocks the self-renewal of cancer stem cells and suppresses tumorigenesis[J]. Cancer Res, 2015, 76 (4): 891-901.
[28]	Wang X, Ma Z, Xiao Z,et al. Chk1 knockdown confers radiosensitization in prostate cancer stem cells[J]. Oncol Rep, 2012, 28 (6): 2247-2254.
[29]	Liu YP, Yang CJ, Huang MS,et al. Cisplatin selects for multidrug-resistant CD133⁺ cells in lung adenocarcinoma by activating Notch signaling[J]. Cancer Res, 2013, 73 (1): 406-416.
[30]	Mcauliffe SM, Morgan SL, Wyant GA,et al. Targeting Notch, a key pathway for ovarian cancer stem cells, sensitizes tumors to platinum therapy[J]. Proc Natl Acad Sci USA, 2012, 109 (43): 2939-2948.
[31]	Xie M, Zhang L, He CS,et al. Activation of Notch-1 enhances epithelial-mesenchymal transition in gefitinib-acquired resistant lung cancer cells[J].J Cell Biochem, 2012, 113 (5): 1501-1513.
[32]	Mabertk, Cojoc M, Peitzsch C,et al. Cancer biomarker discovery: current status and future perspectives[J]. Int J Radiat Biol, 2014, 90 (8): 659-677.
[33]	Fischer M, Yen WC, Kapoun AM,et al. Anti-DLL4 inhibits growth and reduces tumor-initiating cell frequency in colorectal tumors with oncogenic KRAS mutations[J]. Cancer Res, 2011, 71 (5): 1520-1525.
[34]	Noman AS, Uddin M, Rahman MZ,et al. Overexpression of sonic hedgehog in the triple negative breast cancer: clinicopathological characteristics of high burden breast cancer patients from Bangladesh[J]. Sci Rep, 2016, 6:18830.
[35]	Xu M, Gong AH, Yang HQ, et al. Sonic hedgehog-glioma associated oncogene homolog 1 signaling enhances drug resistance in CD44⁺ Musashi-1⁺ gastric cancer stem cells[J]. Cancer Lett, 2015, 369 (1):124-133.

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Get Citation

PDF

XML

Article Metrics

Article views(2807) PDF downloads(918) Cited by()

Proportional views

Advance in resistance mechanism of cancer stem cells therapy

1. College of Traditional Chinese Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China;Renji Hospital, Shanghai Jiaotong University Pharmacy, Shanghai 200127, China

2. Renji Hospital, Shanghai Jiaotong University Pharmacy, Shanghai 200127, China

Received Date: 2016-02-05

Rev Recd Date: 2016-06-15

Key words:

Abstract: Lung cancer is the leading cause of cancer deaths worldwide. Recurrence and metastasis are the primary reasons for its poor prognosis. Growing evidence has proposed that lung cancer may be driven by cancer stem cells (CSCs), which may be responsible for the poor outcome of lung cancer. The resistance mechanisms of cancer stem cells include four aspects: high expression of the chemo-resistant efflux transporter ABC in CSCs populations, over-expression of ALDH, efficient DNA damage repair system, developmental pathway activation. The tolerance mechanism of CSCs was described to provide theoretical basis for clinical treatment and development of new anti-tumor drugs.

HTML

Reference (35)

[1]	Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation[J].Cell, 2011, 144 (5): 646-674.
[2]	Chufan EE, Kapoor K, Ambudkar SV. Drug-protein hydrogen bonds govern the inhibition of the ATPhydrolysis of the multidrug transporter P-glycoprotein[J].Biochem Pharmacol, 2016, (101): 40-53.
[3]	Guan GF, Zhang DJ, Zheng Y,et al. Significance of ATP-binding cassette transporter proteins in multidrug resistance of head and neck squamous cell carcinoma[J].Oncol Lett, 2015, 10 (2): 631-636.
[4]	Xie ZY, Lv K, Xiong Y,et al. ABCG2-meditated multidrug resistance and tumor-initiating capacity of side population cells from colon cancer[J]. Oncol Res Treat, 2014, 37 (11): 666-672.
[5]	Stacy AE, Jansson PJ, Richardson DR. Molecular pharmacology of ABCG2 and its role in chemoresistance[J]. Mol Pharmacol, 2013, 84 (5): 655-669.
[6]	Schexnayder C, Stratford RE. Genistein and Glyceollin effects on ABCC2 (MRP2) and ABCG2 (BCRP) in Caco-2 Cells[J]. Int J Environ Res Public Health, 2015, 13 (1):17-30.
[7]	Hu J, Zhang X, Wang F, et al. Effect of ceritinib (LDK378) on enhancement of chemotherapeutic agents in ABCB1 and ABCG2 overexpressing cells in vitro and in vivo[J]. Oncotarget, 2015, 6 (42): 44643-44659.
[8]	Zhou Q, Ye M, Lu Y,et al. Curcumin improves the tumoricidal effect of mitomycin C by suppressing ABCG2 expression in stem cell-like breast cancer cells[J]. PLoS One, 2015, 10 (8): e0136694.
[9]	Rodriguez-Torres M, Allan AL. Aldehyde dehydrogenase as a marker and functional mediator of metastasis in solid tumors[J]. Clin Exp Metastasis, 2016, 33 (1): 97-113.
[10]	Qiu Y, Pu TJ, Guo P, et al. ALDH⁺/CD44⁺cells in breast cancer are associated with worse prognosis and poor clinical outcome[J]. Exp Mol Pathol, 2016, (100): 145-150.
[11]	Moreb JS, Baker HV, Chang LJ,et al. ALDH isozymes downregulation affects cell growth, cell motility and gene expression in lung cancer cells[J]. Mol Cancer, 2008, 7 (87). doi: 10.1186/1476-4598-7-87.
[12]	Mizuno T, Suzuki N, Makino H,et al. Cancer stem-like cells of ovarian clear cell carcinoma are enriched in the ALDH-high population associated with an accelerated scavenging system in reactive oxygen species[J]. Gynecol Oncol, 2015, 137 (2): 299-305.
[13]	Diehn M, Cho RW, Lobo NA,et al. Association of reactive oxygen species levels and radioresistance in cancer stem cells[J]. Nature, 2009, 458 (7239): 780-783.
[14]	Ajani JA, Wang X, Song S,et al. ALDH-1 expression levels predict response or resistance to preoperative chemoradiation in resectable esophageal cancer patients[J]. Mol Oncol, 2014, 8 (1): 142-149.
[15]	Mi JQ, Li JM, Shen ZX,et al. How to manage acute promyelocytic leukemia[J]. Leukemia, 2012, 26 (8): 1743-1751.
[16]	Parajuli B,Fishel ML,Hurley TD.Selective ALDH3A1 inhibition by benzimidazole analogues increase mafosfamide sensitivity in cancer cells[J].J Med Chem,2014,57 (2):449-461.
[17]	Bartucci M, Svensson S, Romania P, et al. Therapeutic targeting of Chk1 in NSCLC stem cells during chemotherapy[J]. Cell Death Differ, 2012, 19 (5): 768-778.
[18]	Chen Y, Li D, Wang D,et al. Quiescence and attenuated DNA damage response promote survival of esophageal cancer stem cells[J]. J Cell Biochem, 2012, 113 (12): 3643-3652.
[19]	Al-Assar O, Mantoni T, Lunardi S,et al. Breast cancer stem-like cells show dominant homologous recombination due to a larger S-G2fraction[J]. Cancer Biol Ther, 2014, 11 (12): 1028-1035.
[20]	Zhang M, Behbod F, Atkinson RL, et al. Identification of tumor-initiating cells in a p53-null mouse model of breast cancer[J]. Cancer Res, 2008, 68 (12): 4674-4682.
[21]	Bao S, Wu Q, Mclendon RE, et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response[J]. Nature, 2006, 444 (7120): 756-760.
[22]	Yin H, Glass J. The phenotypic radiation resistance of CD44⁺/CD24^-/low breast cancer cells is mediated through the enhanced activation of ATM signaling[J]. PLoS One, 2011, 6 (9): e24080.
[23]	Teng Y, Wang X, Wang Y,et al. Wnt/beta-catenin signaling regulates cancer stem cells in lung cancer A549 cells[J]. Biochem Biophys Res Commun, 2010, 392 (3): 373-379.
[24]	Wang Y, Krivtsov AV, Sinha AU,et al. The Wnt/beta-catenin pathway is required for the development of leukemia stem cells in AML[J]. Science, 2010, 327 (5973): 1650-1653.
[25]	Martins-Neves SR, Paiva-Olivira DI, Wijers-Koster PM, et al. Chemotherapy induces stemness in osteosarcoma cells through activation of Wnt/beta-catenin signaling[J]. Cancer Lett, 2016, 370 (2): 286-295.
[26]	Catalano V, Dentice M, Ambrosio R,et al. Activated thyroid hormone promotes differentiation and chemotherapeutic sensitization of colorectal cancer stem cells by regulating Wnt and BMP4 signaling[J]. Cancer Res, 2015, 76 (5): 1237-1244.
[27]	Fang L, Zhu Q, Neuenschwander M,et al. A small-molecule antagonist of the beta-catenin/TCF4 interaction blocks the self-renewal of cancer stem cells and suppresses tumorigenesis[J]. Cancer Res, 2015, 76 (4): 891-901.
[28]	Wang X, Ma Z, Xiao Z,et al. Chk1 knockdown confers radiosensitization in prostate cancer stem cells[J]. Oncol Rep, 2012, 28 (6): 2247-2254.
[29]	Liu YP, Yang CJ, Huang MS,et al. Cisplatin selects for multidrug-resistant CD133⁺ cells in lung adenocarcinoma by activating Notch signaling[J]. Cancer Res, 2013, 73 (1): 406-416.
[30]	Mcauliffe SM, Morgan SL, Wyant GA,et al. Targeting Notch, a key pathway for ovarian cancer stem cells, sensitizes tumors to platinum therapy[J]. Proc Natl Acad Sci USA, 2012, 109 (43): 2939-2948.
[31]	Xie M, Zhang L, He CS,et al. Activation of Notch-1 enhances epithelial-mesenchymal transition in gefitinib-acquired resistant lung cancer cells[J].J Cell Biochem, 2012, 113 (5): 1501-1513.
[32]	Mabertk, Cojoc M, Peitzsch C,et al. Cancer biomarker discovery: current status and future perspectives[J]. Int J Radiat Biol, 2014, 90 (8): 659-677.
[33]	Fischer M, Yen WC, Kapoun AM,et al. Anti-DLL4 inhibits growth and reduces tumor-initiating cell frequency in colorectal tumors with oncogenic KRAS mutations[J]. Cancer Res, 2011, 71 (5): 1520-1525.
[34]	Noman AS, Uddin M, Rahman MZ,et al. Overexpression of sonic hedgehog in the triple negative breast cancer: clinicopathological characteristics of high burden breast cancer patients from Bangladesh[J]. Sci Rep, 2016, 6:18830.
[35]	Xu M, Gong AH, Yang HQ, et al. Sonic hedgehog-glioma associated oncogene homolog 1 signaling enhances drug resistance in CD44⁺ Musashi-1⁺ gastric cancer stem cells[J]. Cancer Lett, 2015, 369 (1):124-133.

Message Board

Advance in resistance mechanism of cancer stem cells therapy

doi: 10.3969/j.issn.1006-0111.2017.03.001

Abstract

References

Proportional views

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Related

Proportional views